Thiazolidinediones: New Evidence of Bone Loss
نویسندگان
چکیده
منابع مشابه
Thiazolidinediones and bone fractures
The topic of increased risk of bone fracture associated with thiazolidinediones (TZD) treatment first drew international attention when a higher rate of fractures in women with diabetes treated with rosiglitazone was reported in the A Diabetes Outcome Program Trial (ADOPT). Subsequently, a number of clinical trials and observational studies addressing this issue have been reported and most of t...
متن کاملBone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis
Clinical evidence indicates that bone status is affected in patients with type 2 diabetes mellitus (T2DM). Regardless of normal or even high bone mineral density, T2DM patients have increased risk of fractures. One class of antidiabetic drugs, thiazolidinediones (TZDs), causes bone loss and further increases facture risk, placing TZDs in the category of drugs causing secondary osteoporosis. Ris...
متن کاملBone loss: Epidemiology of bone loss
Bone loss occurs when the cellular events of bone formation are quantitatively larger than bone formation. This manuscript discusses the measurement of bone loss, occurrence in the population, risk factors and consequences of bone loss. Recent developments in bone mass measurement and biomarkers have improved our ability to assess bone loss. This process is a normal concomitant of ageing. There...
متن کاملRates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause.
We made longitudinal measurements of bone mineral density (BMD) in 139 normal women (ages 20-88 yr) at midradius (99% cortical bone) and lumbar spine (approximately 70% trabecular bone) by single- and dual-photon absorptiometry. BMD was measured 2-6 (median, 3) times over an interval of 0.8-3.4 yr (median, 2.1 yr). For midradius, BMD did not change (+0.48%/yr, NS) before menopause but decreased...
متن کاملThiazolidinediones on PPARγ: The Roles in Bone Remodeling
Thiazolidinediones (TZDs) are synthetic PPARγ (peroxisome proliferator-activated receptor gamma) agonists and a class of drugs for diabetes mellitus type 2 that can decrease blood sugar efficiently by enhancing insulin sensitivity. However, increased bone fracture risk in diabetic individuals treated with TZDs is one of the reported side effects. Recent studies show that TZDs such as rosiglitaz...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Clinical Endocrinology & Metabolism
سال: 2007
ISSN: 0021-972X,1945-7197
DOI: 10.1210/jc.2007-0328